China: Researchers have found in a new meta-analysis that mepolizumab is an effective and safe treatment for severe ...

What Is Exdensur, and Why Does It Matter? Exdensur (depemokimab) is a new type of ultra long-acting biologic medicine approved by the FDA as an add-on maintenance treatment for severe eosinophilic ...

At a time when demand for biologic medicines is still rising, the approval adds to GSK's respiratory portfolio. Severe eosinophilic asthma affects a smaller group of patients who typically have ...

GSK plc GSK announced that the FDA has approved Exdensur (depemokimab-ulaa), an ultra-long-acting IL-5–targeting biologic, as an add-on maintenance treatment of severe asthma with an eosinophilic ...

The U.S. Food and Drug Administration (FDA) has granted approval to GSK’s Exdensur, a new biologic medication for people with severe eosinophilic asthma aged 12 and older (1). This decision marks a ...

SaveHealth reports seven asthma medication categories, including inhaled corticosteroids and biologics, helping manage ...

The latest announcement is out from Kymera Therapeutics ( (KYMR) ).

Asthma is a chronic inflammatory condition marked by an imbalance in the immune response within the airways. According to Lancet, asthma affects around 339 million people globally. While conventional ...

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult and pediatric patients aged ...

Severe asthma is already treatable with a monthly injectable GSK drug, the blockbuster product Nucala. A new FDA approval gives the drugmaker the opportunity to reach patients with a different ...

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...

China NMPA approves GSK’s Nucala to treat adults with chronic obstructive pulmonary disease: London, UK Tuesday, January 6, 2026, 10:00 Hrs [IST] GSK plc announced that China’ ...